Common adverse reactions The most common side effects (≥30% of patients) listed in the prescribing information include:1 Cytokine release syndrome Rash Fever Itch (pruritus) Fatigue Nausea Chills Abdominal pain Edema Hypotension Dry skin Headache Vomiting Serious adverse reactions The serious adverse reactions listed in the prescribing information include:1 Cytokine release syndrome (CRS) Skin reactions Increased liver enzymes Use in a specific population Kimmtrak (tebentafusp-tebn) may harm your unborn child when given during pregnancy. It is advised to use effective contraception during treatment with Kimmtrak and 1 week after the last dose.1 It is not known if Kimmtrak passes into in your breast milk, but because of the potential for serious adverse reactions in a breastfed child, it is advised not to breastfeed during treatment and for at least 1 week after the last dose.1 For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information.1 References 1. Full prescribing information [FDA]: Kimmtrak (tebentafusp-tebn) [PDF] Immunocore, Jan 2022 2. Tebentafusp: First Treatment to Improve Overall Survival in Metastatic Uveal Melanoma Goodman, A, The ASCO Post, Apr 2021 3. Immunocore announces FDA approval of KIMMTRAK (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma Immunocore press release, Jan 2022